Back to top
more

Vericel (VCEL)

(Delayed Data from NSDQ)

$52.32 USD

52.32
252,448

+0.62 (1.20%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $52.32 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 25.93% and 24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

How Much Upside is Left in Vericel Corporation (VCEL)? Wall Street Analysts Think 53%

The average of price targets set by Wall Street analysts indicates a potential upside of 52.8% in Vericel Corporation (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -46.15% and 3.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 0% and 6.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Vericel Corporation (VCEL) Q4 Earnings Miss Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -47.06% and 0.24%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Vericel Corporation (VCEL) Q4 Earnings Expected to Decline

Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vericel Corporation (VCEL) Reports Q3 Loss, Misses Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -266.67% and -11.12%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Vericel Corporation (VCEL) Q3 Earnings Expected to Decline

Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vericel Corporation (VCEL) Reports Q2 Loss, Tops Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -33.33% and 7.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Vericel Corporation (VCEL) Report Negative Earnings Next Week? What You Should Know

Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exact Sciences, Vericel Corp, Home Depot, ExxonMobil and Discover Financial Services highlighted as Zacks Bull and Bear of the Day

Exact Sciences, Vericel Corp, Home Depot, ExxonMobil and Discover Financial Services highlighted as Zacks Bull and Bear of the Day

Kevin Cook headshot

Bear of the Day: Vericel (VCEL)

Restoring cartilage in sports medicine and rebuilding skin after severe burns gave this small-cap big upside

Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -16.67% and 8.24%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Vericel Corporation (VCEL) Report Negative Earnings Next Week? What You Should Know

Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vericel Corporation (VCEL) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Vericel Corporation (VCEL) closed at $42.92, marking a -0.26% move from the previous day.

Global Blood (GBT) Q4 Earnings Miss, Revenues Beat Estimates

Global Blood (GBT) reports a wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates.

Company News for Feb 25, 2021

Companies In The News Are: VCEL, LNG, HZNP, PRAH

ACADIA (ACAD) Beats on Q4 Earnings, Misses on Revenues

ACADIA's (ACAD) loss narrows in the fourth quarter of 2020 while it misses estimates for revenues. Nuplazid drives year-over-year revenues.

Vericel Corporation (VCEL) Beats Q4 Earnings and Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 19.05% and 0.40%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Blueprint Medicines (BPMC) Q4 Earnings Beat, Revenues In Line

Blueprint Medicines' (BPMC) earnings beat estimates in the fourth quarter of 2020 while revenues meet the same. Shares up.

Vericel Corporation (VCEL) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Vericel Corporation (VCEL) closed at $51.15, marking a -0.04% move from the previous day.

Vericel Corporation (VCEL) Reports Next Week: Wall Street Expects Earnings Growth

Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Has Vericel (VCEL) Outpaced Other Medical Stocks This Year?

Is (VCEL) Outperforming Other Medical Stocks This Year?

CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Fall Y/Y

CRISPR Therapeutics (CRSP) misses estimates for both earnings and revenues in the fourth quarter of 2020. Focus on pipeline development.

Seagen (SGEN) Gets European Commission Nod for Breast Cancer Drug

The European Commission approves Seagen's (SGEN) Tukysa in combination with Herceptin and Xeloda to treat adults with HER2-positive locally advanced or metastatic breast cancer.